In 2019, a research group led by Andrés Ozaita, of the Department of Medicine and Life Sciences at Pompeu Fabra University, ...
Immunovant remains on track for the first of the two batoclimab Phase 3 thyroid eye disease (TED) studies to read out before the end of calendar year 2025. However, due to evolving competitive ...
Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. CAR-T therapy was originally developed for ...
NEW YORK, Nov 5 (Reuters) - The U.S. FDA approved a pricey rare disease drug in September despite findings by its data reviewers that the treatment, while safe, was no more effective than a placebo, a ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced plans to overhaul its approach to therapies for rare diseases. In a position paper, the agency highlighted that rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback